

**REMARKS**

Claims 1, 2, 14, 15, 17 and 22 have been amended Claims 1-5 and 7-26 are pending. Inventorship is not changed by these amendments.

**Response to Objection of claims 2-5**

Claims 2 is objected to as expanding the scope of independent claim 1. While applicants respectfully disagree, in an effort to further prosecution, claim 2 has been rewritten in independent form as suggested by the Examiner.

**Response to Rejection under 35 USC § 101**

Claims 1 and 7-26 are rejected under 35 USC § 101 as not producing a tangible result. Without admitting the propriety of the rejection, and in the interests of furthering the prosecution, independent claims 1, 14, 15, 17 and 22 have been amended to include a physical transformation, as suggested by the Examiner. Specifically, these independent claims now require synthesizing a plurality of secondary protein sequences. Applicants note that claim 2 also requires a physical transformation. Specifically, claim 2 requires producing secondary variant protein sequences in host cells transformed with oligonucleotide sequences.

The Applicants submit that in light of the above amendments and response, the claims are now in condition for allowance and an early notification of such is respectfully solicited. The Examiner is invited to contact the undersigned at (415) 442-1000 if any issues may be resolved in that manner.

**CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. 1.6(a)(4)**

I hereby certify that this correspondence, including listed enclosures, is being electronically transmitted in Portable Document Form (PDF) through EFS-Web via Hyper Text Transfer Protocol to the United States Patent and Trademark Office on:

Dated: February 22, 2007  
Signed: Victoria Poulsen  
Victoria Poulsen

**MORGAN, LEWIS & BOCKIUS LLP**

Dated: 2/22/07  
Customer No.: 67374  
Morgan, Lewis & Bockius LLP  
One Market, Spear Street Tower  
San Francisco, CA 94105  
Telephone: (415) 442-1000  
Facsimile: (415) 442-1001

Robin M. Silva  
Robin M. Silva, Reg. No. 38,304  
Filed Under 37 C.F.R. 1.34